药品名称：FluCide
适应症：既可以用于普通季节性流感又可以用于大流行性流感冒。
FluCide治疗流感疗效优于Oseltamivir
2012年9月10日上午7点钟在WEST HAVEN 城市新闻周刊上，NanoViricides 有限责任公司发布了一项实验研究。该研究指出，口服抗流感药FluCide在患严重H1N1流感的动物模型中起到了很好的保护作用。更重要的是FluCide类抗流感的效果比目前治疗流感的标准口服药物Oseltamivir效果更好，而Oseltamivir是经过各项参数的评估确定的标准抗流感药物。
结果显示与Oseltamivir相比，本实验用到的2种FluCide抗流感药能够显著降低H1N1流感病毒在小鼠肺脏内的水平。肺部炎症和肺组织的破坏被认为是H1N1流感致死率高的主要发病机制，而FluCide能够通过降低肺脏内的H1N1病毒水平来降低H1N1病毒对肺组织的破坏，因此，与Oseltamivir相比FluCide更能够提高H1N1流感生存率。本实验由KARD科技有限公司在之前提到的高致死率的H1N1流感病毒动物模型中开展。
口服FluCide的应用潜力在疾病治疗方面有重要意义。据美国疾病预防控制中心报道，流感是传染性很强的急性呼吸道疾病，是威胁人类健康的主要传染病之一。通过本季度流行病学调查发现，世界5-15%的人群感染过流感（或者说大约3亿至10亿人感染），其中300万至500万各年龄段的人群表现出严重的症状。以往研究发现，即使在非大流行性流感季节美国每年有5%-20%（约4000万人口）的人感染流感病毒，其中20万以上人口因为流感引发的并发症住过院，约36000人死于流感引发的疾病。1918年流感爆发，675000名美国人死于流感，并且多为健康的年轻人。死因大多是由于所谓的“细胞因子风暴”，即体内免疫系统对新病毒入侵的过度反应。
Nanoviricide公司认为口服FluCide不管是单独使用还是与其他抗季节性流感的药物联合使用都能够降低流感导致的严重疾病和死亡。Nanoviricide公司还认为此种药物应用方法比现今治疗流感的标准药物更加有效。
世界卫生组织报道，甲型流感病毒在免疫低下或免疫缺陷的普通人群爆发是对公众健康最大的危害。这种新型病毒能够快速传播，并引发全球大流行性流感，从而导致发病率和致死率的升高。2009甲型流感病毒（禽流感病毒）的快速传播导致的大流行性流感已经证明了这一点。Nanoviricide公司认为FluCide抗流感药物既可以用于普通季节性流感又可以用于大流行性流感冒。
Treatment with NanoViricides FluCide Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus
WEST HAVEN, Conn.--(BUSINESS WIRE)--May 2, 2011 - NanoViricides, Inc. (OTCBB: NNVC.OB) (the "Company") reports that post-infection treatment with its optimized FluCide™ drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection. These findings corroborate the previously reported findings of both increased animal survival and protection of the lungs from influenza virus tissue damage in FluCide-treated animals in the most recent H1N1 influenza study.
The amount of infectious virus in the lungs of the infected animals treated with three of the optimized FluCide™ nanoviricide drug candidates was reduced by greater than 1000-fold as compared to the infected untreated control animals (p-values < 0.001), four days after virus infection. In contrast, animals treated with Oseltamivir (Tamiflu®, Roche) showed less than a 2-fold reduction in lung viral load at the same time point. This indicated a 500-fold greater reduction in viral load by FluCide drug candidates over Oseltamivir.
Of great clinical significance is the fact that 2 of the optimized FluCide™ drug candidates maintained this greatly reduced lung viral load at 7, 13 and 19 days after virus infection in this 21 day study. Thus, treatment with FluCide drug candidates appeared to protect against the complete cycle of infection, virus expansion and spread of infection in the lungs that follows the initial virus infection. This was not the case for the oseltamivir-treated animals. Animals treated with Oseltamivir (Tamiflu®, Roche) showed less than a 2-fold reduction in lung viral load at 4 days and the viral load was increased at 7 days to the same level as that found in the infected, untreated control animals shortly before their death.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the first viral infection. The duration of the study was 21 days.
The Company has previously reported that the same optimized FluCide™ nanoviricide drug candidates achieved significantly increased survival (20.2 to 22.2 days) and greater than 95% reduction in lung inflammation and necrosis in this study. In contrast, animals treated with Oseltamivir showed a mean survival of just 8.3 days and only a 50% reduction in lung inflammation and necrosis.
“The dramatic reduction in the infectious viral load clearly establishes that we have extremely effective, direct-acting, antiviral drug candidates,” said Dr. Randall Barton, Chief Scientific Officer of the Company.
“Such a strong viral load reduction would enable even bird-flu infected patients to recover readily, assuming these results hold in humans,” said Eugene Seymour, MD, MPH, CEO of the CompanTreatment with NanoViricides FluCide Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus
WEST HAVEN, Conn.--(BUSINESS WIRE)--May 2, 2011 - NanoViricides, Inc. (OTCBB: NNVC.OB) (the "Company") reports that post-infection treatment with its optimized FluCide™ drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection. These findings corroborate the previously reported findings of both increased animal survival and protection of the lungs from influenza virus tissue damage in FluCide-treated animals in the most recent H1N1 influenza study.
The amount of infectious virus in the lungs of the infected animals treated with three of the optimized FluCide™ nanoviricide drug candidates was reduced by greater than 1000-fold as compared to the infected untreated control animals (p-values < 0.001), four days after virus infection. In contrast, animals treated with Oseltamivir (Tamiflu®, Roche) showed less than a 2-fold reduction in lung viral load at the same time point. This indicated a 500-fold greater reduction in viral load by FluCide drug candidates over Oseltamivir.
Of great clinical significance is the fact that 2 of the optimized FluCide™ drug candidates maintained this greatly reduced lung viral load at 7, 13 and 19 days after virus infection in this 21 day study. Thus, treatment with FluCide drug candidates appeared to protect against the complete cycle of infection, virus expansion and spread of infection in the lungs that follows the initial virus infection. This was not the case for the oseltamivir-treated animals. Animals treated with Oseltamivir (Tamiflu®, Roche) showed less than a 2-fold reduction in lung viral load at 4 days and the viral load was increased at 7 days to the same level as that found in the infected, untreated control animals shortly before their death.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the first viral infection. The duration of the study was 21 days.
The Company has previously reported that the same optimized FluCide™ nanoviricide drug candidates achieved significantly increased survival (20.2 to 22.2 days) and greater than 95% reduction in lung inflammation and necrosis in this study. In contrast, animals treated with Oseltamivir showed a mean survival of just 8.3 days and only a 50% reduction in lung inflammation and necrosis.
“The dramatic reduction in the infectious viral load clearly establishes that we have extremely effective, direct-acting, antiviral drug candidates,” said Dr. Randall Barton, Chief Scientific Officer of the Company.
“Such a strong viral load reduction would enable even bird-flu infected patients to recover readily, assuming these results hold in humans,” said Eugene Seymour, MD, MPH, CEO of the Company.y.
